Status:
COMPLETED
Sitagliptin Cardiovascular Outcomes Study (MK-0431-082)
Lead Sponsor:
Merck Sharp & Dohme LLC
Collaborating Sponsors:
Duke Clinical Research Institute, Oxford Diabetes Trials Unit
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
50+ years
Phase:
PHASE3
Brief Summary
This is a clinical trial designed to assess the cardiovascular outcome of long-term treatment with sitagliptin used as part of usual care compared to usual care without sitagliptin in participants wit...
Eligibility Criteria
Inclusion
- Has T2DM
- Has HbA1c between 6.5% (48 mmol/mol) and 8.0% (64 mmol/mol) on stable dose(s) of antihyperglycemic agent(s), including insulin
- Has pre-existing cardiovascular disease
Exclusion
- Has a history of type 1 diabetes mellitus or ketoacidosis.
- Is not able to take sitagliptin
Key Trial Info
Start Date :
December 10 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 30 2015
Estimated Enrollment :
14671 Patients enrolled
Trial Details
Trial ID
NCT00790205
Start Date
December 10 2008
End Date
March 30 2015
Last Update
November 23 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.